Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Investing Activities (2016 - 2026)

Heron Therapeutics filings provide 15 years of Cash from Investing Activities readings, the most recent being -$939000.0 for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 141.31% to -$939000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $12.8 million, a 35.07% decrease, with the full-year FY2025 number at $16.0 million, down 14.45% from a year prior.
  • Cash from Investing Activities hit -$939000.0 in Q1 2026 for Heron Therapeutics, up from -$5.5 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $36.8 million in Q1 2023 to a low of -$36.0 million in Q3 2022.
  • Median Cash from Investing Activities over the past 5 years was $2.3 million (2025), compared with a mean of $2.9 million.
  • Biggest five-year swings in Cash from Investing Activities: skyrocketed 351.98% in 2022 and later tumbled 537.21% in 2023.
  • Heron Therapeutics' Cash from Investing Activities stood at $2.0 million in 2022, then tumbled by 537.21% to -$8.8 million in 2023, then skyrocketed by 229.22% to $11.4 million in 2024, then crashed by 147.78% to -$5.5 million in 2025, then skyrocketed by 82.79% to -$939000.0 in 2026.
  • The last three reported values for Cash from Investing Activities were -$939000.0 (Q1 2026), -$5.5 million (Q4 2025), and $11.9 million (Q3 2025) per Business Quant data.